Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022
Live webcast to be hosted on Wednesday, November 23, 2022 at 1:30 pm CET PARIS–(BUSINESS WIRE)–Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced that it will host a live webcast on Wednesday, November 23, 2022 at 1:30 pm CET to provide updates … [Read more…]
